

INTRODUCTION AND PROJECT DESCRIPTION	5
a) Introduction	5
b) Project Objectives.....	5
c) Project Approach.....	5
SECTION I. AN OVERVIEW OF REMS	8
a) The Arrival of REMS	8
b) REMS Triggers	8
c) Elements of a REMS Program.....	8
d) REMS Approvals to Date	11
e) FDA Approval Process for REMS.....	11
SECTION II. IMPACT OF REMS ON KEY SUPPLY CHAIN STAKEHOLDERS	12
a) Manufacturer Approach to REMS	12
1) Manufacturer Perception of REMS	12
2) Challenges for Manufacturers and Impact on the Supply Chain.....	14
3) Implications for Manufacturers and Lessons Learned.....	17
b) Distributor Approach to REMS	20
1) Distributor Perception of REMS	20
2) REMS Challenges for Distributors.....	21
3) Future Implications for Distributors	24
c) Provider Approach to REMS	26
1) Provider Perception of REMS.....	26
2) Channel-Specific REMS Challenges for Providers.....	28
SECTION III. ECONOMIC CONSIDERATIONS FOR REMS PROGRAMS	32
a) Manufacturers	33
b) Distributors	34
c) Providers	35
d) Concluding Thoughts Regarding Economic Considerations	36
SECTION IV: TWO REMS PROGRAM CASE STUDIES	37
a) Retail Pharmacy Case Study: Isotretinoin	37
b) Specialty Pharmacy Case Study: Romiplostim (Nplate™) and Eltrombopag (Promacta™)	41
CONCLUSIONS AND RECOMMENDATIONS TO IMPROVE REMS	47
APPENDIX A. PRODUCTS DEEMED TO HAVE “IN EFFECT” AN APPROVED REMS	49
APPENDIX B. CURRENTLY APPROVED PRODUCTS WITH REMS PROGRAMS	50
APPENDIX C. SOURCES	57